Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
210 CHF | -0.24% |
|
-0.24% | +15.51% |
May. 28 | HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal | MT |
May. 23 | HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart - Surperformance
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.51% | 1.59B | - | ||
+21.12% | 3.17B | B- | ||
+12.50% | 1.76B | - | - | |
-11.54% | 1.22B | - | - | |
+39.59% | 960M | B+ | ||
+8.05% | 657M | - | ||
+49.87% | 629M | - | D+ | |
-4.17% | 502M | - | - | |
+19.25% | 455M | - | - | |
+34.29% | 331M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HBMN Stock
- HBMNE Stock
- Ratings HBM Healthcare Investments AG